Full Professor in Biomedical Engineering
The University Medical Center Groningen
University of Groningen

Prof. Santos (D.Sc. Tech., Chem. Eng.) is a Full Professor in Department of Biomedical Engineering and Head of the Department of Biomedical Engineering at the University Medical Center Groningen/University of Groningen. He was previously Full Professor in Pharmaceutical Nanotechnology, Director of Doctoral Program in Drug Research (University of Helsinki), Fellow Member of Helsinki Institute of Life Science, Director of the FinPharmaNet in Finland, and Chair of CRS Focus Group in Nanomedicine and Nanoscale Delivery. He is also Research Director and Head of Nanomedicines and Biomedical Engineering Group at the University of Helsinki, Faculty of Pharmacy. Prof. Santos is also the Chairman and co-founder of Capsamedix Oy, and Coordinator of H2020 EU MSCA-ITN P4 FIT network. He holds Visiting Professorships at the Shanghai Jiao Tong University School of Medicine (China) and University of Tartu (Estonia). Prof. Santos research interests include the development of nanoparticles/nanomedicines and biomaterials for biomedical applications, particularly cancer and heart diseases. His lab makes the unique bridge between medical engineering, pharmaceutical nanotechnology and tissue engineering by combining unique techniques to develop novel therapeutic formulations, including industrial scale-up validation, batch-to-batch reproducibility, and controllability of the biomaterials’ physicochemical properties for translation into the clinic. He is co-author of +400 publications (+14600 citations; h-index = 72) and 4 patents. He has +181 invited talks around the world. Prof. Santos has received prestigious awards/grants, e.g., the “Talent Prize in Science” in 2010 attributed by the Portuguese Government, ERC Starting Grant in 2013 and ERC Proof-of-Concept Grant in 2018, Young Researcher Award in 2013 attributed by Faculty of Pharmacy, the Academy of Finland Award for Social Impact in 2016, and the CRS Young Investigator Award 2021.